EGFR and non-small cell lung carcinoma: The use of osimertinib in combination with the MEK inhibitor trametinib has been reported as a fifth line therapy in a patient with NSCLC and EGFR exon 19del and an AGK-BRAF fusion, observing a partial response to this treatment [114].